前沿生物药业（南京）股份有限公司2025年度业绩快报公告

Core Viewpoint - The company reported a total revenue of 143.67 million yuan for 2025, marking a 10.96% increase from the previous year, primarily driven by sales of its innovative HIV drug and other products [3][4] Financial Performance and Status - The company experienced a net loss attributable to shareholders of 261.72 million yuan, an increase in loss of 60.33 million yuan compared to the previous year, mainly due to the absence of investment income from the disposal of subsidiary equity in 2024 [3] - The total assets at the end of the reporting period were 1.586 billion yuan, a decrease of 12.49% from the beginning of the year, while the equity attributable to the parent company decreased by 22.52% to 884 million yuan [3] Business Operations - The core product, the HIV drug, maintained its position as the preferred medication in the inpatient and severe cases, with outpatient market revenue continuing to grow after being included in the medical insurance directory [4] - The company successfully launched a new infrared therapy patch, establishing a distributor management team and actively expanding online marketing channels [4] Research and Development - The company increased its R&D investment, focusing on a multi-layered pipeline that includes antiviral business, small nucleic acid innovative drugs, and high-end generic drugs [5] - Significant progress was made in small nucleic acid drug development, with several candidates entering various stages of research and regulatory processes [5] - An exclusive licensing agreement was signed with GSK, providing the company with a $40 million upfront payment and potential milestone payments totaling up to $950 million, which will support core R&D and financial optimization [6]